Literature DB >> 19995818

Complications: tracking down the data on oseltamivir.

Deborah Cohen1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19995818     DOI: 10.1136/bmj.b5387

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  11 in total

1.  Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials.

Authors:  Miguel A Hernán; Marc Lipsitch
Journal:  Clin Infect Dis       Date:  2011-06-15       Impact factor: 9.079

2.  The imperative to share clinical study reports: recommendations from the Tamiflu experience.

Authors:  Peter Doshi; Tom Jefferson; Chris Del Mar
Journal:  PLoS Med       Date:  2012-04-10       Impact factor: 11.069

3.  Why we need easy access to all data from all clinical trials and how to accomplish it.

Authors:  Peter C Gøtzsche
Journal:  Trials       Date:  2011-11-23       Impact factor: 2.279

Review 4.  Neuraminidase inhibitors for preventing and treating influenza in adults and children.

Authors:  Tom Jefferson; Mark A Jones; Peter Doshi; Chris B Del Mar; Rokuro Hama; Matthew J Thompson; Elizabeth A Spencer; Igho Onakpoya; Kamal R Mahtani; David Nunan; Jeremy Howick; Carl J Heneghan
Journal:  Cochrane Database Syst Rev       Date:  2014-04-10

5.  The Tamiflu fiasco and lessons learnt.

Authors:  Yogendra Kumar Gupta; Meenakshi Meenu; Prafull Mohan
Journal:  Indian J Pharmacol       Date:  2015 Jan-Feb       Impact factor: 1.200

6.  Epidemiological characteristics and low case fatality rate of pandemic (H1N1) 2009 in Japan.

Authors:  Taro Kamigaki; Hitoshi Oshitani
Journal:  PLoS Curr       Date:  2009-12-20

Review 7.  The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews.

Authors:  Barbara Michiels; Karolien Van Puyenbroeck; Veronique Verhoeven; Etienne Vermeire; Samuel Coenen
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

8.  Biosafety data as confidential business information.

Authors:  Kaare M Nielsen
Journal:  PLoS Biol       Date:  2013-03-05       Impact factor: 8.029

9.  Restoring invisible and abandoned trials: a call for people to publish the findings.

Authors:  Peter Doshi; Kay Dickersin; David Healy; S Swaroop Vedula; Tom Jefferson
Journal:  BMJ       Date:  2013-06-13

Review 10.  [Pandemic influenza A/H1N1 2009 : Challenge for intensive care medicine].

Authors:  M A Bürkle; L Frey; B Zwissler
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.